# Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient

> **NCT01858207** · PHASE2 · UNKNOWN · sponsor: **Shi-Ming Lin** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Transcatheter Arterial Chemoembolization
- **PROCEDURE:** Radiofrequency ablation
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT01858207
- **Lead sponsor:** Shi-Ming Lin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01858207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01858207, "Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01858207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*